

Samuel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5482530/publications.pdf>

Version: 2024-02-01

244
papers

27,002
citations

28190

55
h-index

5965

160
g-index

244
all docs

244
docs citations

244
times ranked

21945
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2012, 141, e419S-e496S.	0.4	3,745
2	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426
3	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
4	Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2009, 361, 2342-2352.	13.9	2,330
5	Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2011, 123, 1788-1830.	1.6	1,842
6	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019, 380, 752-762.	13.9	886
7	Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. <i>Circulation</i> , 2014, 129, 764-772.	1.6	824
8	Pulmonary embolism and deep vein thrombosis. <i>Lancet</i> , The, 2012, 379, 1835-1846.	6.3	809
9	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1382-1392.	1.1	648
10	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 2240-2252.	13.9	557
11	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	3.8	515
12	Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 365, 2167-2177.	13.9	512
13	Risk Factors for Venous Thromboembolism. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1-7.	1.2	456
14	A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. <i>American Journal of Cardiology</i> , 2004, 93, 259-262.	0.7	452
15	Echocardiography in the Management of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2002, 136, 691.	2.0	407
16	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
17	Acute Pulmonary Embolism: Part I. <i>Circulation</i> , 2003, 108, 2726-2729.	1.6	362
18	Pulmonary embolism. <i>Lancet</i> , The, 2004, 363, 1295-1305.	6.3	357

#	ARTICLE	IF	CITATIONS
19	A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1401-1410.	1.1	280
20	Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis. <i>American Journal of Medicine</i> , 2015, 128, 747-759.e2.	0.6	231
21	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2060-2072.	1.2	230
22	Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism. <i>Circulation</i> , 1995, 92, 2800-2802.	1.6	208
23	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
24	New Onset of Venous Thromboembolism Among Hospitalized Patients at Brigham and Women's Hospital Is Caused More Often by Prophylaxis Failure Than by Withholding Treatment. <i>Chest</i> , 2000, 118, 1680-1684.	0.4	204
25	Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. <i>Circulation</i> , 2019, 139, 1162-1173.	1.6	196
26	Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis. <i>Chest</i> , 2002, 122, 1933-1937.	0.4	181
27	Venous thromboembolism: Epidemiology and magnitude of the problem. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 235-242.	0.7	176
28	More than an anticoagulant: Do heparins have direct anti-inflammatory effects?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 437-444.	1.8	160
29	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
30	Acute Pulmonary Embolism: Part II. <i>Circulation</i> , 2003, 108, 2834-2838.	1.6	134
31	Inferior Vena Cava Filters to Prevent Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1587-1597.	1.2	134
32	Normal d-dimer levels in emergency department patients suspected of acute pulmonary embolism. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1475-1478.	1.2	127
33	Peripheral Artery Disease: Past, Present, and Future. <i>American Journal of Medicine</i> , 2019, 132, 1133-1141.	0.6	123
34	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016, 129, 1198-1204.	0.6	121
35	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1245-1252.	0.7	115
36	Prospective Study of Moderate Alcohol Consumption and Risk of Peripheral Arterial Disease in US Male Physicians. <i>Circulation</i> , 1997, 95, 577-580.	1.6	103

#	ARTICLE	IF	CITATIONS
37	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000â€“18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.	5.2	100
38	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65.	0.7	94
39	Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. <i>JAMA Internal Medicine</i> , 2015, 175, 1112.	2.6	84
40	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014, 167, 335-341.	1.2	81
41	Cost-effectiveness of warfarin: Trial versus â€œreal-worldâ€œ stroke prevention in atrial fibrillation. <i>American Heart Journal</i> , 2009, 157, 1064-1073.	1.2	77
42	A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , 2011, 118, 205-205.	0.6	77
43	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
44	Warfarin and Vascular Calcification. <i>American Journal of Medicine</i> , 2016, 129, 635.e1-635.e4.	0.6	73
45	Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ^Â , RE-COVER ^Â , II, and RE-MEDY ^Â . <i>Vascular Medicine</i> , 2016, 21, 506-514.	0.8	71
46	Axial and Reformatted Four-Chamber Right Ventricleâ€“toâ€“Left Ventricle Diameter Ratios on Pulmonary CT Angiography as Predictors of Death After Acute Pulmonary Embolism. <i>American Journal of Roentgenology</i> , 2012, 198, 1353-1360.	1.0	69
47	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 574.	3.8	69
48	Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 8, 139-142.	1.0	68
49	Pulmonary Embolism and Deep Vein Thrombosis. <i>Circulation</i> , 2002, 106, 1436-1438.	1.6	65
50	Pulmonary Embolism Thrombolysis. <i>Circulation</i> , 1997, 96, 716-718.	1.6	64
51	Thrombolysis for Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2002, 347, 1131-1132.	13.9	63
52	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	0.8	62
53	Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1027-1035.	1.2	61
54	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.	1.6	61

#	ARTICLE	IF	CITATIONS
55	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	1.2	59
56	Comparison of ECG-gated versus non-gated CT ventricular measurements in thirty patients with acute pulmonary embolism. <i>International Journal of Cardiovascular Imaging</i> , 2009, 25, 101-107.	0.7	57
57	Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 8-23.e18.	0.9	55
58	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	1.8	55
59	Prevention of Venous Thromboembolism Among Hospitalized Medical Patients. <i>Circulation</i> , 2005, 111, e1-3.	1.6	50
60	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019, 94, 21-28.	2.0	50
61	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Over Journal, 2017, 185, 93-100.	1.2	48
62	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2046-2052.	1.8	48
63	Thrombolysis in Pulmonary Embolism. <i>Circulation</i> , 2001, 104, 2876-2878.	1.6	44
64	Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. <i>Vascular Medicine</i> , 2016, 21, 400-407.	0.8	44
65	Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoralâ€“Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 633-644.	1.8	44
66	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 408-411.	1.2	44
67	Thrombolytic Therapy for Patients With Pulmonary Embolism Who Are Hemodynamically Stable But Have Right Ventricular Dysfunction. <i>Archives of Internal Medicine</i> , 2005, 165, 2197.	4.3	42
68	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
69	Comparison of Fatal or Irreversible Events With Extendedâ€“Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40
70	Prevention of Deep Vein Thrombosis and Pulmonary Embolism. <i>Circulation</i> , 2004, 110, e445-7.	1.6	39
71	Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2045-2052.	1.8	36
72	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020, 190, 555-561.	1.2	36

#	ARTICLE	IF	CITATIONS
73	Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. <i>Vascular Medicine</i> , 2019, 24, 442-451.	0.8	35
74	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). <i>European Heart Journal</i> , 2020, 41, 1086-1096.	1.0	35
75	Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. <i>American Journal of Medicine</i> , 2018, 131, 1408-1417.	0.6	34
76	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.	1.8	34
77	Gastrointestinal Complications of Dual Antiplatelet Therapy. <i>Circulation</i> , 2006, 113, e655-8.	1.6	33
78	Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 35-40.	1.0	33
79	Risk factors for major bleeding in the SEATTLE II trial. <i>Vascular Medicine</i> , 2017, 22, 44-50.	0.8	33
80	Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <i>Oncologist</i> , 2021, 26, e8-e16.	1.9	31
81	Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	0.8	30
82	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	1.9	30
83	Pulmonary Embolism After Coronary Artery Bypass Grafting. <i>Circulation</i> , 2004, 109, 2712-2715.	1.6	29
84	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018, 131, 972.e1-972.e7.	0.6	29
85	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309.	1.4	29
86	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	1.8	28
87	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.	2.8	28
88	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. <i>Circulation</i> , 2018, 137, 91-94.	1.6	27
89	Optimal Duration of Anticoagulation After Venous Thromboembolism. <i>Circulation</i> , 2011, 123, 664-667.	1.6	26
90	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 787-794.	0.2	26

#	ARTICLE	IF	CITATIONS
91	Expanding anticoagulation management services to include direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 274-280.	1.0	26
92	Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. <i>Hospital Practice (1995)</i> , 2015, 43, 249-257.	0.5	24
93	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
94	Treatment of acute pulmonary embolism with dabigatran versus warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 714-721.	1.8	24
95	Evaluation of a Device Combining an Inferior Vena Cava Filter and a Central Venous Catheter for Preventing Pulmonary Embolism Among Critically Ill Trauma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1248-1254.	0.2	22
96	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.	1.8	22
97	Let's Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. <i>Circulation</i> , 2018, 138, 2591-2593.	1.6	22
98	Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. <i>International Journal of Cardiology</i> , 2018, 268, 137-142.	0.8	22
99	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 45.	1.3	22
100	Epidemiology of Pulmonary Embolism. <i>Seminars in Vascular Medicine</i> , 2001, 01, 139-146.	2.1	21
101	Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary) $T_j ETQq1 1 0.784314 \text{ rgBT} / \text{Over}$	0.7	20
102	DVT Prevention: What Is Happening in the "Real World"? <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 023-032.	1.5	20
103	Prevention of Recurrent Idiopathic Venous Thromboembolism. <i>Circulation</i> , 2004, 110, IV-20-IV-24.	1.6	20
104	Four key questions surrounding thrombolytic therapy for submassive pulmonary embolism. <i>Vascular Medicine</i> , 2016, 21, 47-52.	0.8	20
105	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987603.	0.7	20
106	Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etxilate Is Maintained Over 1 Year of Post-Treatment Follow-up. <i>Blood</i> , 2012, 120, 21-21.	0.6	20
107	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.	1.2	19
108	Venous thromboembolism risk among hospitalized patients: Magnitude of the risk is staggering. <i>American Journal of Hematology</i> , 2007, 82, 775-776.	2.0	18

#	ARTICLE	IF	CITATIONS
109	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1317-1325.	1.8	18
110	Venous Thromboembolism in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 159-162.	1.2	18
111	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	0.6	18
112	Low Intensity Warfarin Anticoagulation is Safe and Effective as a Long-Term Venous Thromboembolism Prevention Strategy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 51-52.	1.0	17
113	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019, 45, 477-487.	3.9	17
114	Treatment of Pulmonary Thromboembolism.. <i>Internal Medicine</i> , 1999, 38, 620-625.	0.3	16
115	Treatment of Blood Clots. <i>Circulation</i> , 2002, 106, e138-40.	1.6	16
116	Inflammation and Myocardial Infarction. <i>Circulation</i> , 2014, 130, e334-6.	1.6	16
117	Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. <i>European Heart Journal</i> , 2014, 35, 1836-1843.	1.0	16
118	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
119	Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. <i>Vascular Medicine</i> , 2016, 21, 361-368.	0.8	15
120	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.	1.5	15
121	Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children. <i>Chest</i> , 2022, 161, 791-802.	0.4	15
122	Catheter-directed thrombolysis for deep vein thrombosis: 2021 update. <i>Vascular Medicine</i> , 2021, 26, 662-669.	0.8	15
123	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
124	Syncope (Fainting). <i>Circulation</i> , 2016, 133, e600-2.	1.6	14
125	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. <i>American Heart Journal</i> , 2017, 189, 1-8.	1.2	14
126	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.	1.8	14

#	ARTICLE	IF	CITATIONS
127	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 1-8.	1.0	14
128	PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. <i>BMJ Open</i> , 2021, 11, e041845.	0.8	14
129	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3031-3043.	1.9	14
130	Association of ABO blood group type with cardiovascular events in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 584-586.	1.0	14
131	Deep venous thrombosis: early discharge strategies and outpatient management. , 1999, 7, 113-122.		13
132	PEITHO Long-Term Outcomes Study. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1545-1548.	1.2	13
133	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017, 01, e82-e91.	0.7	13
134	Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009903.	1.3	13
135	Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. <i>Journal of the American Heart Association</i> , 2021, 10, e021117.	1.6	13
136	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
137	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	1.5	13
138	Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 582-582.	0.6	13
139	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020, 120, 924-936.	1.8	12
140	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.	1.0	11
141	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , 2022, 12, e060000.	0.8	11
142	Case 17-2004. <i>New England Journal of Medicine</i> , 2004, 350, 2281-2290.	13.9	10
143	Eradication of hospital-acquired venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1089-1092.	1.8	10
144	Selection Bias, Orthopaedic Style. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 631-633.	1.4	10

#	ARTICLE	IF	CITATIONS
145	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PEâ„ Study. American Journal of Medicine, 2020, 133, 936-945.	0.6	10
146	Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. Blood, 2013, 122, 212-212.	0.6	10
147	Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. Blood, 2013, 122, 2375-2375.	0.6	10
148	Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis, 2003, 89, 953-8.	1.8	10
149	Unsolved Issues in the Treatment of Pulmonary Embolism. Thrombosis Research, 2001, 103, V245-V255.	0.8	9
150	How chest CT for the diagnosis of pulmonary embolism (PE) has changed my professional life: Reflections from a PE doctor. Seminars in Roentgenology, 2005, 40, 8-10.	0.2	9
151	Acute Pulmonary Embolism: Risk Stratification. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 153-156.	0.5	9
152	Percutaneous mechanical thrombectomy for massive pulmonary embolism: Improve safety and efficacy by sharing information. Catheterization and Cardiovascular Interventions, 2007, 70, 807-808.	0.7	9
153	Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. American Heart Journal, 2015, 169, 186-187.	1.2	9
154	Requiem for Liberalizing Indications for Vena Caval Filters?. Circulation, 2016, 133, 1992-1994.	1.6	9
155	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 227-232.	1.0	9
156	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. JAMA Internal Medicine, 2019, 179, 263.	2.6	9
157	External validation of the SOXâ„PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 1381-1389.	1.9	9
158	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thrombosis Research, 2021, 203, 155-162.	0.8	9
159	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	1.3	9
160	Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDYâ„. Blood, 2014, 124, 1544-1544.	0.6	9
161	European Atherosclerosis Society Screening Recommendations for Lipoprotein(a) and High-Sensitivity C-Reactive Protein: Double Standard or Failure of Evidence-Based Medicine?. Clinical Chemistry, 2010, 56, 1544-1546.	1.5	8
162	Competing risk analysis in a large cardiovascular clinical trial: An <sc>APEX</sc> substudy. Pharmaceutical Statistics, 2017, 16, 445-450.	0.7	8

#	ARTICLE	IF	CITATIONS
163	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018, 02, e16-e24.	0.7	8
164	Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1686-1694.	1.8	8
165	Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008747.	1.4	8
166	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, , .	1.9	8
167	Temporal trends in abdominal aortic aneurysmal disease: a nationwide cohort study on cardiovascular morbidity and medical cardioprotective therapy. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1957-1964.	0.8	8
168	Management of deep venous thrombosis and pulmonary embolism. <i>Clinical Cornerstone</i> , 2000, 2, 47-55.	1.0	7
169	Prophylaxis of venous thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 225-235.	0.4	7
170	Peripherally Inserted Central Catheters. <i>Chest</i> , 2011, 140, 6-7.	0.4	7
171	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018, 02, e33-e38.	0.7	7
172	Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988000.	0.7	7
173	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019, 139, 1234-1236.	1.6	7
174	Dabigatran Etxilate Versus Warfarin in the Treatment of Venous Thromboembolism.. <i>Blood</i> , 2009, 114, 1-1.	0.6	7
175	Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVERÂ„¢ and RE-COVERÂ„¢ II. <i>Blood</i> , 2014, 124, 594-594.	0.6	7
176	Diagnosis of pulmonary embolism. <i>Clinical Cornerstone</i> , 2000, 2, 38-45.	1.0	6
177	Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. <i>Vascular</i> , 2017, 25, 54-62.	0.4	6
178	Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVERÂ„¢, RE-COVERÂ„¢ II, and RE-MEDYÂ„¢. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 484-489.	1.0	6
179	Risk Stratification Model: Lower-Extremity Ultrasonography for Hospitalized Patients with Suspected Deep Vein Thrombosis. <i>Journal of General Internal Medicine</i> , 2018, 33, 21-25.	1.3	6
180	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.	1.0	6

#	ARTICLE	IF	CITATIONS
181	Thromboembolism Prophylaxis for Patients Discharged From the Hospital. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3148-3150.	1.2	6
182	Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 1136-1136.	0.6	6
183	Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , 1988, 38, 303-312.	1.2	5
184	Similarity in Presentation and Response to Thrombolysis Among Women and Men with Pulmonary Embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 95-100.	1.0	5
185	Women and Heart Attacks. <i>Circulation</i> , 2016, 133, e428-9.	1.6	5
186	Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw281.	3.0	5
187	Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 257-263.	1.0	5
188	Net clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.	1.9	5
189	The Approach to Massive Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2000, 21, 541-548.	0.8	4
190	Outpatient venous thromboembolism: the importance of optimum prophylaxis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 12-13.	3.3	4
191	Obstructive Sleep Apnea. <i>Circulation</i> , 2015, 132, e114-6.	1.6	4
192	Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. <i>American Journal of Cardiology</i> , 2020, 133, 175-178.	0.7	4
193	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	1.6	4
194	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	1.8	4
195	Pulmonary embolism in Black Americans. <i>American Journal of Hematology</i> , 2010, 85, 465-466.	2.0	3
196	Counterpoint: Should Coagulopathy Be Repaired Prior to Central Venous Line Insertion? No. <i>Chest</i> , 2012, 141, 1142-1144.	0.4	3
197	A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. <i>Journal of Visualized Experiments</i> , 2015, , e52761.	0.2	3
198	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. <i>Vascular Medicine</i> , 2017, 22, 324-330.	0.8	3

#	ARTICLE	IF	CITATIONS
199	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 54-61.	0.6	3
200	Cautionary Notes About Outpatient Treatment of Acute Pulmonary Embolism. <i>Chest</i> , 2018, 154, 233-234.	0.4	3
201	Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. <i>Chest</i> , 2019, 156, 200-202.	0.4	3
202	Pulmonary Embolism in Patients With Syncope. <i>Journal of the American College of Cardiology</i> , 2019, 74, 755-758.	1.2	3
203	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 331-335.	1.0	3
204	ECMO and Surgical Embolectomy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 912-915.	1.2	3
205	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	1.0	3
206	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	1.0	3
207	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	0.8	3
208	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	0.8	3
209	Diagnosis of deep venous thrombosis. <i>Clinical Cornerstone</i> , 2000, 2, 29-35.	1.0	2
210	Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 371-374.	1.0	2
211	Improving Clinician Performance of Inpatient Venous Thromboembolism Risk Assessment and Prophylaxis. <i>Hospital Practice (1995)</i> , 2013, 41, 123-131.	0.5	2
212	Pharmacomechanical Therapy for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2018, 378, 1752-1753.	13.9	2
213	Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. <i>TH Open</i> , 2018, 02, e229-e232.	0.7	2
214	Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. <i>European Heart Journal</i> , 2019, 40, 1515-1517.	1.0	2
215	How the Results of a Randomized Trial of Catheter-Directed Thrombolysis Versus Anticoagulation alone for Submassive Pulmonary Embolism Would Affect Patient and Physician Decision Making: Report of an Online Survey. <i>Journal of Clinical Medicine</i> , 2019, 8, 215.	1.0	2
216	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 281-290.	1.0	2

#	ARTICLE	IF	CITATIONS
217	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020, 186, 78-79.	0.8	2
218	Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes. <i>American Journal of Medicine</i> , 2021, 134, 1419-1423.	0.6	2
219	Post-Hoc Analysis of RE-MEDYâ„¢ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism. <i>Blood</i> , 2014, 124, 4270-4270.	0.6	2
220	Deep Venous Thrombosis: Early Discharge Strategies and Outpatient Management. , 1997, 4, 365-374.		1
221	Magnetic resonance angiography and venography were sensitive but had poor technical adequacy for diagnosing pulmonary embolism. <i>Annals of Internal Medicine</i> , 2010, 153, J1.	2.0	1
222	Preventing DVT in Peripherally Inserted Central Catheters. <i>Chest</i> , 2013, 143, 589-590.	0.4	1
223	Nursing Home Residents with Venous Thrombosis: A Vulnerable, Fragile and Disenfranchised Population. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1507-1508.	1.8	1
224	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	0.7	1
225	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.2	1
226	Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110379.	0.7	1
227	Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1023-1031.	1.0	1
228	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.2	1
229	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. <i>Thrombosis Research</i> , 2022, 211, 63-69.	0.8	1
230	Early Detection and Management of Venous Thrombosis in Skull Base Surgery: Role of Routine Doppler Ultrasound Monitoring. <i>Neurosurgery</i> , 2022, 91, 115-122.	0.6	1
231	Possible requiem: trial-and-error warfarin. <i>Blood</i> , 2007, 110, 1404-1405.	0.6	0
232	Response to Letter Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study". <i>Circulation</i> , 2008, 117, .	1.6	0
233	Venous thromboembolism: "an ounce of prevention is worth a pound of cure". <i>Thrombosis and Haemostasis</i> , 2015, 113, 1174-1175.	1.8	0
234	Giants in Chest Medicine. <i>Chest</i> , 2017, 152, 463-465.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion. TH Open, 2018, 02, e49-e53.	0.7	0
236	Thromboprophylaxis Strategies in Acute Medically Ill Patients. Current Emergency and Hospital Medicine Reports, 2019, 7, 118-126.	0.6	0
237	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. Journal of Thrombosis and Thrombolysis, 2020, 52, 158-160.	1.0	0
238	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. Journal of Thrombosis and Thrombolysis, 2021, 51, 561-570.	1.0	0
239	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2021, 52, 22-29.	1.0	0
240	Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes – Double trouble when vascular medicine emergencies meet. Vascular Medicine, 2021, , 1358863X2110296.	0.8	0
241	Dabigatran Etxilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVERY® and RE-COVER II, . Blood, 2015, 126, 4730-4730.	0.6	0
242	The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq0 0 0 rgBT /Overlock 10 T 3824-3824.	0.6	0
243	Pulmonary embolism diagnosis: remember the history and physical exam. Thrombosis and Haemostasis, 2009, 101, 7-8.	1.8	0
244	Do take that break. Harvard Business Review, 2009, 87, 30, 128.	3.1	0